1094 related articles for article (PubMed ID: 27854145)
21. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations.
Jansook P; Pichayakorn W; Ritthidej GC
Drug Dev Ind Pharm; 2018 Oct; 44(10):1693-1700. PubMed ID: 29936874
[TBL] [Abstract][Full Text] [Related]
22. Topical Amphotericin B solid lipid nanoparticles: Design and development.
Butani D; Yewale C; Misra A
Colloids Surf B Biointerfaces; 2016 Mar; 139():17-24. PubMed ID: 26700229
[TBL] [Abstract][Full Text] [Related]
23. Investigating effect of microemulsion components: In vitro permeation of ketoconazole.
Patel MR; Patel RB; Parikh JR; Solanki AB; Patel BG
Pharm Dev Technol; 2011 Jun; 16(3):250-8. PubMed ID: 20146553
[TBL] [Abstract][Full Text] [Related]
24. Microemulsion based gel for topical dermal delivery of pseudolaric acid B: In vitro and in vivo evaluation.
Wan T; Xu T; Pan J; Qin M; Pan W; Zhang G; Wu Z; Wu C; Xu Y
Int J Pharm; 2015 Sep; 493(1-2):111-20. PubMed ID: 26216411
[TBL] [Abstract][Full Text] [Related]
25. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
26. Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis.
Sosa L; Clares B; Alvarado HL; Bozal N; Domenech O; Calpena AC
Nanomedicine; 2017 Oct; 13(7):2303-2312. PubMed ID: 28712917
[TBL] [Abstract][Full Text] [Related]
27. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
28. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
29. Preparation, Characterization, and Formulation Optimization of Ionic-Liquid-in-Water Nanoemulsions toward Systemic Delivery of Amphotericin B.
Esson MM; Mecozzi S
Mol Pharm; 2020 Jun; 17(6):2221-2226. PubMed ID: 32343901
[TBL] [Abstract][Full Text] [Related]
30. Chitosan functionalized poly (ε-caprolactone) nanoparticles for amphotericin B delivery.
Vásquez Marcano RGDJ; Tominaga TT; Khalil NM; Pedroso LS; Mainardes RM
Carbohydr Polym; 2018 Dec; 202():345-354. PubMed ID: 30287009
[TBL] [Abstract][Full Text] [Related]
31. Synergetic skin targeting effect of hydroxypropyl-β-cyclodextrin combined with microemulsion for ketoconazole.
Che J; Wu Z; Shao W; Guo P; Lin Y; Pan W; Zeng W; Zhang G; Wu C; Xu Y
Eur J Pharm Biopharm; 2015 Jun; 93():136-48. PubMed ID: 25845772
[TBL] [Abstract][Full Text] [Related]
32. Stability and transdermal absorption of topical amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Int J Pharm; 2004 Feb; 270(1-2):279-86. PubMed ID: 14726142
[TBL] [Abstract][Full Text] [Related]
33. Novel microemulsion-based gel formulation of tazarotene for therapy of acne.
Patel MR; Patel RB; Parikh JR; Patel BG
Pharm Dev Technol; 2016 Dec; 21(8):921-932. PubMed ID: 26334480
[TBL] [Abstract][Full Text] [Related]
34. Role of architecture of N-oxide surfactants in the design of nanoemulsions for Candida skin infection.
Lewińska A; Jaromin A; Jezierska J
Colloids Surf B Biointerfaces; 2020 Mar; 187():110639. PubMed ID: 31776055
[TBL] [Abstract][Full Text] [Related]
35. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
[TBL] [Abstract][Full Text] [Related]
36. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment.
Nimtrakul P; Tiyaboonchai W; Lamlertthon S
Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675
[TBL] [Abstract][Full Text] [Related]
37. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy.
Fu T; Yi J; Lv S; Zhang B
J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177
[TBL] [Abstract][Full Text] [Related]
38. Preparation and Characterization of Nanostructured Lipid Carriers for Improved Topical Drug Delivery: Evaluation in Cutaneous Leishmaniasis and Vaginal Candidiasis Animal Models.
Riaz A; Hendricks S; Elbrink K; Guy C; Maes L; Ahmed N; Kiekens F; Khan GM
AAPS PharmSciTech; 2020 Jul; 21(5):185. PubMed ID: 32632542
[TBL] [Abstract][Full Text] [Related]
39. Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery.
Ledet G; Pamujula S; Walker V; Simon S; Graves R; Mandal TK
Drug Dev Ind Pharm; 2014 Mar; 40(3):370-9. PubMed ID: 23600657
[TBL] [Abstract][Full Text] [Related]
40. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
